U.S. Markets close in 4 hrs 28 mins

Acorda Therapeutics, Inc. (ACOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.6866-0.0104 (-1.49%)
As of 11:29AM EDT. Market open.

Acorda Therapeutics, Inc.

420 Saw Mill River Road
Ardsley 10502
United States
914 347 4300
http://www.acorda.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees344

Key Executives

NameTitlePayExercisedYear Born
Dr. Ron CohenFounder, CEO, Pres & Director827.95kN/A1956
Mr. David LawrenceCTO, Chief of Bus. Operations & Principal Accounting Officer480.9kN/A1958
Ms. Jane WasmanConsultant1.85MN/A1956
Ms. Lauren M. SabellaChief Commercial Officer490.07kN/A1961
Dr. Burkhard BlankChief Medical Officer and Head of R&D662.5kN/A1955
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Corporate Governance

Acorda Therapeutics, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.